In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

VUG ETF invests in large-cap growth stocks. Check out 3 key reasons why the fund might not be a good choice from a portfolio ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

The Vanguard US Total Market Shares Index ETF (ASX: VTS) outperformed the Vanguard Australian Shares Index ETF (ASX: VAS) by ...

ETFs across various categories pulled in $17.7 billion in capital last week, with U.S. fixed-income ETFs leading the way.

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Index funds are one of the most popular types of investments because of their simplicity, low cost and diversification ...

Unlike the Dow, the S&P 500 GARP Index selects 75 stocks from the broader S&P 500 based on "growth scores" and "composite scores" for quality and value. Growth scores rely on metr ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...